Tired of the confusion around pleural effusions: Adenosine deaminase detection sets the record straight!

Pleural effusion, characterized by the accumulation of fluid in the pleural space, poses significant challenges in clinical practice, especially in determining whether it belongs to the inflammatory exudates or non-inflammatory transudates. Adenosine deaminase (ADA), an enzyme primarily produced by immune cells, particularly lymphocytes, increase in response to inflammatory conditions, including tuberculosis and malignancies. Elevated ADA levels in pleural have been shown to correlate with inflammatory exudates, making it a valuable biomarker for differentiating between inflammatory and non-inflammatory effusions. Moreover, numerous studies have demonstrated the treatment function of ADA in inflammation- related pleural effusion syndrome. Recently, research has established the values for the implication of ADA in diagnosing and managing pleural disease. Based on these findings, ADA becomes a reliable, non-invasive marker for early diagnosis and the appropriate treatment for pleural inflammation, ultimately improving patient outcomes.